Amatera
Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A synthetic biology company engineering microbes to produce novel biologic drugs.
OncologyImmunologyRare Diseases
Technology Platform
A proprietary synthetic biology platform that engineers microbial systems for the discovery and scalable production of novel biologic therapeutics.
Opportunities
Potential to disrupt biologic drug manufacturing and enable new protein-based therapies through cost-effective and flexible production.
Risk Factors
Technical risks in scaling microbial fermentation for human-grade therapeutics and potential immunogenicity of non-mammalian produced proteins.
Competitive Landscape
Competes with large CDMOs and other synthetic biology platforms on the ability to produce complex, functional biologics efficiently and at scale.